tech20171026_8k.htm

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): October 26, 2017

 

BIO-TECHNE CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

Minnesota

(State or Other Jurisdiction of Incorporation)

 

  0-17272

       (Commission File Number)

41-1427402

(I.R.S. Employer

Identification No.)

 

614 McKinley Place NE

Minneapolis, MN 55413

(Address of Principal Executive Offices) (Zip Code)

 

Registrant's telephone number, including area code: (612) 379-8854

 

Not Applicable

(Former Name or Former Address, if changed since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

☐     Written communications pursuant to Rule 425 under the Securities Act 17 CFR 230.425)

 

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company        ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

Item 5.07     Submission of Matters to a Vote of Security Holders

 

A quorum was present at the Annual Meeting with 35,782,997 shares represented personally or by proxy, which represents approximately 96% of the outstanding shares of the Company's common stock. The voting results at the Annual Meeting were as set forth below.

 

Proposal No. 1 – The shareholders voted to set the number of directors at ten:

 

For

Against

Abstain

Broker Non-Vote

33,943,200

161,735

39,722

1,638,290

 

Proposal No. 2 – The shareholders elected each of the nominees to the Board of Directors:

 

 

For

Against

Abstain

Broker Non-Vote

Charles R. Kummeth

33,826,769

294,961

22,977

1,638,290

Robert V. Baumgartner

33,727,937

391,840

24,930

1,638,290

Randolph C. Steer, M.D., Ph.D.

32,878,733

1,241,597

24,377

1,638,290

Charles A. Dinarello, M.D.

14,835,527

19,284,504

24,676

1,638,290

Karen A. Holbrook, Ph.D.

33,178,208

944,284

22,215

1,638,290

John L. Higgins

32,929,670

1,190,446

24,591

1,638,290

Roeland Nusse, Ph.D.

33,813,075

306,899

24,733

1,638,290

Harold J. Wiens

33,194,386

925,529

24,792

1,638,290

Joseph D. Keegan, Ph.D.

33,868,071

251,837

24,799

1,638,290

Alpna Seth, Ph.D.

33,869,105

249,757

25,845

1,638,290

 

With the exception of Dr. Dinarello, who will offer to tender his resignation for consideration under the process described in the Company’s Principles of Corporate Governance, each nominee was elected by a majority voting standard defined in the Amended and Restated Articles of Incorporation.

 

Proposal No. 3 – The shareholders adopted a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Company’s Proxy Statement for the Annual Meeting:

 

For

Against

Abstain

Broker Non-Vote

19,312,038

14,686,971

145,698

1,638,290

 

Proposal No. 4 – The shareholders adopted a non-binding resolution approving “one year” for the frequency of the Company’s advisory votes on executive compensation:

 

1 Year

2 Years

3 Years

Abstain

33,763,492

11,663

209,174

160,378

 

Proposal No. 5 – The shareholders approved the Company’s Second Amended and Restated 2010 Equity Incentive Plan:

 

For

Against

Abstain

Broker Non-Vote

31,648,433

2,399,958

96,316

1,638,290

 

Proposal No. 6 – The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2018.

 

For

Against

Abstain

Broker Non-Vote

35,263,729

427,948

91,320

N/A

 

- 2 -

 

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

 

10.1

Second Amended and Restated 2010 Equity Incentive Plan.

 

 

10.2

Form of Director NonQualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

 

 

10.3

Form of Employee NonQualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

 

 

10.4

Form of Incentive Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

 

 

10.5

Form of Performance Unit Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

 

 

10.6

Form of Restricted Stock Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

 

 

10.7

Form of Restricted Stock Unit Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated: October 26, 2017

 

 

BIO-TECHNE CORPORATION

 

       

 

 

 

 

 

 

/s/ Brenda S. Furlow

 

 

 

Brenda S. Furlow

 

 

 

Senior Vice President, General Counsel and Secretary

 

 

- 3 -

 

 

  Exhibit No.

Description

     
 

10.1

Second Amended and Restated 2010 Equity Incentive Plan.

 

 

10.2

Form of Director NonQualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

 

 

10.3

Form of Employee NonQualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

 

 

10.4

Form of Incentive Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

 

 

10.5

Form of Performance Unit Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

 

 

10.6

Form of Restricted Stock Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

 

 

10.7

Form of Restricted Stock Unit Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

 

- 4 -